72 results about "Acute lymphoblastic leukemias" patented technology

The invention discloses a method for constructing humanized Ph chromosome positive acute lymphocytic leukemia mouse model, and the method comprises the following steps: acquisition of leukemia cells, pretreatment of NOD/SCID mouse and implantation of leukemia cells, and implantation of leukemia cells. Specifically, the method comprises: 60Co irradiation of sub-lethal dose combined with a pretreatment with rat anti-mouse CD122 monoclonal antibody, and injection of Ph+ALL bone marrow mononuclear cells from knee joint marrow cavity of NOD/SCID mouse, thereby a humanized Ph+ALL mouse model is established with high molding efficiency and good repeatability; cell sorting is not needed, and the molding process is easy to be operated; the method provides an experiment platform for carrying out mankind Ph+ALL research on the level of living animals, and will promote deep research of domestic Ph+ALL.

The present invention relates to methods for predicting the outcome of therapeutic intervention in cases of leukemia, especially acute lymphoblastic leukemia in children and adults. The present invention evaluates a gene expression profile and identifies prognostic genes of cancers, in particular leukemia, more particularly B-precursor acute lymphoblastic leukemia (ALL). The present invention provides a method of determining prognosis of leukemia, in particular, acute lymphoblastic leukemia, more particularly B-precursor ALL and predicting therapeutic outcome of a patient. The method comprises the steps of first establishing the threshold value of at least three prognostic genes of leukemia, preferably at least eight prognostic genes, or preferably, as many as 26 prognostic genes. Then, the amount of the prognostic gene(s) from a leukemia patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene(s) which is indicative of therapeutic success or failure, whereby the prognostic outcome of the patient is determined/predicted.

The invention relates to the technical field of medical detection, in particular to a detection kit for minute residues of B-cell acute lymphocyte leukemia. The detection kit comprises anti CD10, CD19, CD20, CD34, CD38 and CD45 antibodies labeled by different fluoresceins. The detection kit comprises six monoclonal antibody combinations of leukocyte differentiation antigen, and a fluorescence labeling and flow cytometric detection technology is combined to realize that one-time flow cytometric detection can quickly and accurately identify the level and typing of abnormal cells of the minute residues of the B-cell acute lymphocyte leukemia, the obtained detection index can be used as an intermediate result to intuitively judge the prognosis conditions of B-cell acute lymphocyte leukemia patients, and thus important guiding significance is provided for the formulation of clinical treatment schemes for the leukemia patients.

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.

The invention relates to tubulin depolymerizing agent polypeptides and application thereof, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The invention is characterized in that the sequence of the tubulin depolymerizing agent polypeptides 1 is CRALERLV disclosed as SEQ NO.1. The invention also relates to application of the tubulin depolymerizing agent polypeptides 1 in preparation of medicines for treating acute lymphatic leukemia. A solid-phase synthesis method is utilized to chemically synthesize the tubulin depolymerizing agent polypeptides 1; and the polypeptides with the bran-new sequence can inhibit tubulin in vitro and treat acute lymphatic leukemia.

The invention discloses a kit for detecting gene mutation of acute lymphoblastic leukemia based on multiplex-PCR targeted high-throughput sequencing and a detection method of the kit. The kit is usedfor detecting multiple exon regions of 19 genes related with the acute lymphoblastic leukemia. The kit contains a primer working solution for detecting relevant gene mutation, a PCR mixed solution, aPCR reaction solution, a digestion solution, a joint P5 and a joint P7. The kit is used for carrying out detection based on a multiplex-PCR targeted high-throughput sequencing technique, has the advantages of high accuracy, sensitivity and throughput and can be used for rapidly and efficiently carrying out standardized quantitative detection on 19 relevant genes of acute lymphoblastic leukemia (ALL).

The invention provides a mouse model of acute lymphoblastic leukemia and a modeling method, and relates to the field of biotechnology. The preparation method comprises the following steps: infecting IL-7 stimulated hematopoietic cells with retroviruses with BCR-ABLP190; and transfusing the stimulated hematopoietic cells to syngenic mice. The method has the advantages of being simple and easy to implement in a modeling process and capable of establishing the ph+ALL mouse model in one step. According to the mouse model of the acute lymphoblastic leukemia provided by the invention, the sorted BCR-ABL+B cells are transfused to the syngenic mice for the second time without irradiation treatment, with performance consistent with that of mice of first episode; the model is good in stability; and in addition, the uniformity of recipient mice is enhanced and such risks as accidental death of the recipient mice due to irradiation are reduced.

The invention relates to the field of diagnosis kits, and particularly relates to a pair of primer and kit for detecting the specific gene HB-1 of acute B lymphocyte leukemia. The primers for detecting the HB-1 and a probe are an upstream primer sequence as shown in SEQ ID NO:1, a downstream primer sequence as shown in SEQ ID NO:2 and a probe as shown in SEQ ID NO:3; the 5'end of a nucleotide sequence as shown in the SEQ ID NO:3 has a Fam mark, and the 3'end of the nucleotide sequence has a Tamra mark. The kit disclosed by the invention optimizes the probe sequence, simplifies the experimental step, realizes the single step of a detection method, enhances the experimental stability and realizes the quantitative detection of the gene HB-1.

The invention belongs to the field of medicine and molecular detection, in particular to a detection kit for relapse and drug resistance gene mutation of acute lymphoblastic leukemia (ALL) and an application method thereof. The detection kit includes a specific primer for an NT5C2 gene mutation site, which can comprehensively and accurately detect the high mutation site of an NT5C2 gene. The detection result has strong guiding significance for clinical practice, can be used for rapid and accurate detection of relapse and drug resistance of ALL to avoid unnecessary therapeutic drugs and is of great importance in the filed of detection and treatment of ALL. Through mutation detection of the NT5C2 gene related to ALL relapse and drug resistance, the detection kit can better guide the medication and treatment of clinicians, and can be used as an auxiliary means for diagnosis of relapse and drug resistance of the disease.

The invention discloses application of fatsia japonica branch and leaf extractives to anti-cancer drug preparation and preparation of the fatsia japonica branch and leaf extractives, and belongs to the technical field of medicines and natural medicines. A preparation method of the fatsia japonica branch and leaf extractives includes the following steps: ethyl alcohol with 95-percent concentration serves as extracting agents; an ultrasonic extraction method is adopted for extracting fatsia japonica branches and leaves; total ethyl alcohol extractives of the fatsia japonica branch and leaf extractives are obtained; petroleum ether, chloroform and ethyl acetate are sequentially used for extracting the total ethyl alcohol extractives; a petroleum ether part, a chloroform part, an ethyl acetate part and an extraction remaining part are obtained. Meanwhile, supersonic extraction is carried out on the fatsia japonica branches and leaves obtained after extraction with the ethyl alcohol is carried out with distilled water, and an aqueous extract part is obtained. The five extraction parts of the fatsia japonica branches and leaves are of great significance in preparing medicines for treating the breast cancer, the non-small cell lung cancer and the human B-cell acute lymphoblastic leukemia.

The invention relates to succinyl hydrazine compounds derivative and medical compound containing them; and the application of it in preparing medicine that resists leukemia. The succinyl hydrazine compounds derivative shows inhibiting action to BCR-Ab1 tyrosine kinase activity through pharmacological test. It is characterized by high effecivity and low toxicity, and can be widly used to prepare medicine that treats chronic granulocytic leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia, especially medicine treating patient that generates drug resistance to Gleevec.

The embodiment of the invention provides an ALL prognostic related gene mutation detection method, primers and a kit. PCR and sequencing technologies are used, specific primers are mainly used for amplifying specific exon sections of CREBBP genes in genome DNA, sequencing is conducted on target fragments obtained through amplification through a sequencing reaction, and whether mutation exists or not is detected by comparing the obtained sequence with a standard genetic sequence. The detection process is rapid and sensitive, operation is easy, the accuracy is high, and the detection result is definite and clear; the detection specificity is high, a gene mutation detection method which is the most accurate at present is adopted, and purposiveness is high; the blood collection amount of a detection specimen is low, a detected object himself/herself is benefited, fewer experimental instruments are used in the detection process, and the cost is reduced. The invention aims at obtaining analytical data capable of being used for medication guidance and prognosis evaluation of acute lymphoblastic leukemia, and the analytical data can play an important role in the field of medical detection.

The invention discloses a primer probe set, kit and method for quantitative detection of an expression level of a small integral membrane protein 3 (SMIM3) gene. The primer probe set comprises a component A and a component B; the component A includes a forward primer SMIM3-FP, a reverse primer SMIM3-RP and a probe SMIM3-probe; and the component B includes a forward primer ABL1-FP, a reverse primerABL1-RP and a probe ABL1-probe. The primer probe set, the kit and the method have the advantages that quantitative detection of the relative expression level of the SMIM3 gene in a cell is realized;moreover, the sensitivity of the SMIM3 gene and the sensitivity of an ABL1 gene both reach up to 100 copies; the sensitivity is high, results are accurate, and the reliability is high; a new auxiliarydiagnosis method or auxiliary identification method is provided for hematologic tumor cells (especially acute myelogenous leukemia and acute lymphoblastic leukemia); and the primer probe set, the kitand the method have broader application prospects.

The present invention discloses a kit for simultaneously detecting mutations of genes NBPF10, TSFM, PRB2 and DIAPH1, wherein the kit comprises a plurality of multi-gene capture probes, can be used fordetecting the somatic mutations and the germline mutations at the tumor genome level, can be used for the assisted diagnosis of patients with hematological tumors (especially acute lymphoblastic leukemia patients), the monitoring of minimal residual diseases, the evaluation of prognosis, and the like, and can provide important effect in the field of medical detection, wherein the detection methodis simple and sensitive.

The invention discloses an application of combination of andrographolide and dexamethasone to preparation of compound medicines for resisting acute lymphoblastic leukemia, and belongs to the technicalfield of medicines. The combination of the andrographolide and the dexamethasone can be used for preparing the compound medicines for resisting acute lymphoblastic leukemia. An autophagy process is restrained, so that the expression of effect target of dexamethasone -glucocorticoid receptors is increased, and sensibility of organisms to the dexamethasone is improved. A new application field of the andrographolide and the dexamethasone is opened up, new compound medicines for resisting acute lymphoblastic leukemia are also opened up, and the combination has positive pharmaceutical value and broad social significance. The invention further discloses the compound medicines for resisting acute lymphoblastic leukemia. The compound medicines for resisting acute lymphoblastic leukemia can effectively treat the acute lymphoblastic leukemia, and are obvious in treatment effect, and small in toxic and side effect, and reverse tolerance is not liable to generate.

The ectopic expression of Mer receptor tyrosine kinase (Mer) has been identified as a tumor cell survival gene product in Acute Lymphoblastic Leukemia (ALL) cells and a potential cause of ALL chemoresistance. Hence, we investigated whether the development of small molecule Mer inhibitors was possible. A first aspect of the present invention is a compound (sometimes referred to as an “active compound” herein) of Formula I, IA, or IB.